DOCSLIB.ORG

YERVOY (Ipilimumab) Injection Is Available As Follows

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
YERVOY (Ipilimumab) Injection Is Available As Follows HIGHLIGHTS OF PRESCRIBING INFORMATION x Unresectable or metastatic melanoma: These highlights do not include all the information needed to use YERVOY o YERVOY 3 mg/kg every 3 weeks for a total of 4 doses. (2.2) safely and effectively. See full prescribing information for YERVOY. x Adjuvant melanoma: YERVOY (ipilimumab) injection, for intravenous use o YERVOY 10 mg/kg every 3 weeks for 4 doses, followed by 10 mg/kg Initial U.S. Approval: 2011 every 12 weeks for up to 3 years or until documented disease recurrence or unacceptable toxicity. (2.3) x Advanced renal cell carcinoma: WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS o Nivolumab 3 mg/kg followed by YERVOY 1 mg/kg on the same day, See full prescribing information for complete boxed warning. every 3 weeks for 4 doses, then nivolumab 240 mg every 2 weeks or YERVOY can result in severe and fatal immune-mediated adverse 480 mg every 4 weeks. (2.4) reactions. These immune-mediated reactions may involve any organ x Microsatellite instability-high (MSI-H) or mismatch repair deficient system; however, the most common severe immune-mediated adverse (dMMR) metastatic colorectal cancer: reactions are enterocolitis, hepatitis, dermatitis (including toxic o Nivolumab 3 mg/kg followed by YERVOY 1 mg/kg on the same day epidermal necrolysis), neuropathy, and endocrinopathy. The majority every 3 weeks for 4 doses, then nivolumab 240 mg every 2 weeks or of these immune-mediated reactions initially manifested during 480 mg every 4 weeks. (2.5) treatment; however, a minority occurred weeks to months after x Hepatocellular carcinoma: discontinuation of YERVOY. o Nivolumab 1 mg/kg followed by YERVOY 3 mg/kg on the same day Permanently discontinue YERVOY and initiate systemic high-dose every 3 weeks for 4 doses, then nivolumab 240 mg every 2 weeks or corticosteroid therapy for severe immune-mediated reactions. (2.8) 480 mg every 4 weeks. (2.6) Assess patients for signs and symptoms of enterocolitis, dermatitis, x Metastatic non-small cell lung cancer neuropathy, and endocrinopathy and evaluate clinical chemistries o Nivolumab 3 mg/kg every 2 weeks with YERVOY 1 mg/kg every including liver function tests, adrenocorticotropic hormone (ACTH) 6 weeks. (2.7) level, and thyroid function tests at baseline and before each dose. (5.1, o Nivolumab 360 mg every 3 weeks with YERVOY 1 mg/kg every 6 5.2, 5.3, 5.4, 5.5) weeks and 2 cycles of platinum-doublet chemotherapy. (2.7) x Permanently discontinue for severe adverse reactions. (2.8) --------------------------RECENT MAJOR CHANGES---------------------------- Indications and Usage (1) 5/2020 ----------------------DOSAGE FORMS AND STRENGTHS--------------------- Dosage and Administration (2) 5/2020 Injection: 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL) in a single- Warnings and Precautions (5) 5/2020 use vial. (3) ---------------------------INDICATIONS AND USAGE---------------------------- ------------------------------CONTRAINDICATIONS------------------------------- YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking None. (4) antibody indicated for: Melanoma ------------------------WARNINGS AND PRECAUTIONS----------------------- x Treatment of unresectable or metastatic melanoma in adults and pediatric Immune-mediated adverse reactions: Permanently discontinue for severe patients (12 years and older). (1.1) reactions. Withhold dose for moderate immune-mediated adverse reactions x Adjuvant treatment of patients with cutaneous melanoma with pathologic until return to baseline, improvement to mild severity, or complete resolution, involvement of regional lymph nodes of more than 1 mm who have and patient is receiving less than 7.5 mg prednisone or equivalent per day. undergone complete resection, including total lymphadenectomy. (1.2) Administer systemic high-dose corticosteroids for severe, persistent, or Renal Cell Carcinoma (RCC) recurring immune-mediated reactions. (5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 5.10) x Treatment of patients with intermediate or poor-risk, previously untreated advanced renal cell carcinoma, in combination with nivolumab. (1.3) x Immune-mediated hepatitis: Evaluate liver function tests before each dose Colorectal Cancer of YERVOY. (5.2) Withhold for moderate and permanently discontinue for severe or life-threatening transaminase or total bilirubin elevation. (5.2) x Treatment of adult and pediatric patients 12 years of age and older with microsatellite instability-high (MSI-H) or mismatch repair deficient x Immune-mediated endocrinopathies: Monitor clinical chemistries, ACTH (dMMR) metastatic colorectal cancer that has progressed following level, and thyroid function tests prior to each dose. Evaluate at each visit for treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in signs and symptoms of endocrinopathy. Institute hormone replacement combination with nivolumab. This indication is approved under accelerated therapy as needed. (5.5) approval based on overall response rate and duration of response. Continued x Immune-mediated pneumonitis: Withhold for moderate and permanently approval for this indication may be contingent upon verification and discontinue for severe or life-threatening pneumonitis. (5.6) description of clinical benefit in confirmatory trials. (1.4) x Immune-mediated nephritis and renal dysfunction: Monitor for changes in Hepatocellular Carcinoma renal function. Withhold for moderate or severe and permanently x Treatment of patients with hepatocellular carcinoma who have been discontinue for life-threatening serum creatinine elevation. (5.7) previously treated with sorafenib, in combination with nivolumab. This x Immune-mediated encephalitis: Monitor for changes in neurologic function. indication is approved under accelerated approval based on overall response Withhold for new-onset moderate to severe neurological signs or symptoms rate and duration of response. Continued approval for this indication may be and permanently discontinue for immune-mediated encephalitis. (5.8) contingent upon verification and description of clinical benefit in Infusion reactions: Discontinue for severe and life-threatening infusion confirmatory trials. (1.5) x reactions. Interrupt or slow the rate of infusion in patients with mild or Non-Small Cell Lung Cancer (NSCLC) moderate infusion reactions. (5.9) x Treatment of adult patients with metastatic non-small cell lung cancer Embryo-Fetal toxicity: Can cause fetal harm. Advise of potential risk to a expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no x fetus and use of effective contraception. (5.11, 8.1, 8.3) EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) -------------------------------ADVERSE REACTIONS------------------------------ x Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line Most common adverse reactions (t5%) with YERVOY as a single agent are treatment, in combination with ipilimumab and 2 cycles of platinum-doublet fatigue, diarrhea, pruritus, rash, and colitis. Additional common adverse chemotherapy (1.6) reactions at the 10 mg/kg dose (t5%) include nausea, vomiting, headache, weight loss, pyrexia, decreased appetite, and insomnia. (6.1) ------------------------DOSAGE AND ADMINISTRATION---------------------- Most common adverse reactions (t20%) with YERVOY in combination with x Administer by intravenous infusion based upon recommended infusion rate nivolumab are fatigue, rash, pruritus, diarrhea, musculoskeletal pain, cough, for each indication. (2) 1 Reference ID: 4614238 pyrexia, decreased appetite, nausea, abdominal pain, arthralgia, headache, To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers vomiting, dyspnea, dizziness, hypothyroidism, and decreased weight. (6.1) Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Most common adverse reactions (≥20%) with YERVOY in combination with nivolumab and platinum-doublet chemotherapy are fatigue, musculoskeletal ------------------------USE IN SPECIFIC POPULATIONS----------------------- pain, nausea, diarrhea, rash, decreased appetite, constipation, and pruritus. (6.1) x Lactation: Discontinue breastfeeding during treatment with YERVOY. (8.2) See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 5/2020 FULL PRESCRIBING INFORMATION: CONTENTS * WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS 5.12 Risks Associated When Administered in Combination with 1 INDICATIONS AND USAGE Nivolumab 1.1 Unresectable or Metastatic Melanoma 6 ADVERSE REACTIONS 1.2 Adjuvant Treatment of Melanoma 6.1 Clinical Trials Experience 1.3 Advanced Renal Cell Carcinoma 6.2 Immunogenicity 1.4 Microsatellite Instability-High (MSI-H) or Mismatch Repair 6.3 Postmarketing Experience Deficient (dMMR) Metastatic Colorectal Cancer 7 DRUG INTERACTIONS 1.5 Hepatocellular Carcinoma 8 USE IN SPECIFIC POPULATIONS 1.6 Metastatic Non-Small Cell Lung Cancer 8.1 Pregnancy 2 DOSAGE AND ADMINISTRATION 8.2 Lactation 2.1 Patient Selection 8.3 Females and Males of Reproductive Potential 2.2 Recommended Dosing for Unresectable or Metastatic 8.4 Pediatric Use Melanoma 8.5 Geriatric Use 2.3 Recommended Dosing for Adjuvant Treatment of 8.6 Renal Impairment Melanoma 8.7 Hepatic Impairment 2.4 Recommended Dosing for Renal Cell Carcinoma 10 OVERDOSAGE 2.5 Recommended Dosing for Colorectal Cancer 11 DESCRIPTION 2.6 Recommended Dosing for Hepatocellular Carcinoma 12 CLINICAL PHARMACOLOGY 2.7 Recommended Dosing for Metastatic NSCLC 12.1
Load more

Recommended publications
  • Cutaneous Adverse Effects of Biologic Medications
    REVIEW CME MOC Selena R. Pasadyn, BA Daniel Knabel, MD Anthony P. Fernandez, MD, PhD Christine B. Warren, MD, MS Cleveland Clinic Lerner College Department of Pathology Co-Medical Director of Continuing Medical Education; Department of Dermatology, Cleveland Clinic; of Medicine of Case Western and Department of Dermatology, W.D. Steck Chair of Clinical Dermatology; Director of Clinical Assistant Professor, Cleveland Clinic Reserve University, Cleveland, OH Cleveland Clinic Medical and Inpatient Dermatology; Departments of Lerner College of Medicine of Case Western Dermatology and Pathology, Cleveland Clinic; Assistant Reserve University, Cleveland, OH Clinical Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH Cutaneous adverse effects of biologic medications ABSTRACT iologic therapy encompasses an expo- B nentially expanding arena of medicine. Biologic therapies have become widely used but often As the name implies, biologic therapies are de- cause cutaneous adverse effects. The authors discuss the rived from living organisms and consist largely cutaneous adverse effects of tumor necrosis factor (TNF) of proteins, sugars, and nucleic acids. A clas- alpha inhibitors, epidermal growth factor receptor (EGFR) sic example of an early biologic medication is inhibitors, small-molecule tyrosine kinase inhibitors insulin. These therapies have revolutionized (TKIs), and cell surface-targeted monoclonal antibodies, medicine and offer targeted therapy for an including how to manage these reactions
    [Show full text]
  • International Consensus Guidance for Management of Myasthenia Gravis 2020 Update
    VIEWS & REVIEWS OPEN ACCESS LEVEL OF RECOMMENDATION International Consensus Guidance for Management of Myasthenia Gravis 2020 Update Pushpa Narayanaswami, MBBS, DM, Donald B. Sanders, MD, Gil Wolfe, MD, Michael Benatar, MD, Correspondence Gabriel Cea, MD, Amelia Evoli, MD, Nils Erik Gilhus, MD, Isabel Illa, MD, Nancy L. Kuntz, MD, Janice Massey, MD, Dr. Narayanaswami Arthur Melms, MD, Hiroyuki Murai, MD, Michael Nicolle, MD, Jacqueline Palace, MD, David Richman, MD, and pnarayan@ Jan Verschuuren, MD bidmc.harvard.edu Neurology® 2021;96:114-122. doi:10.1212/WNL.0000000000011124 Abstract Objective To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness method was used to develop consensus recommendations pertaining to 7 treatment topics. In February 2019, the international panel was reconvened with the addition of one member to represent South America. All previous recommendations were reviewed for currency, and new consensus recommendations were developed on topics that required inclusion or updates based on the recent literature. Up to 3 rounds of anonymous e-mail votes were used to reach consensus, with modifications to recommendations between rounds based on the panel input. A simple majority vote (80% of panel members voting “yes”) was used to approve minor changes in grammar and syntax to improve clarity. Results The previous recommendations for thymectomy were updated. New recommendations were developed for the use of rituximab, eculizumab, and methotrexate as well as for the following topics: early immunosuppression in ocular MG and MG associated with immune checkpoint inhibitor treatment.
    [Show full text]
  • Annex I Summary of Product Characteristics
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT YERVOY 5 mg/ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of concentrate contains 5 mg ipilimumab. One 10 ml vial contains 50 mg of ipilimumab. One 40 ml vial contains 200 mg of ipilimumab. Ipilimumab is a fully human anti-CTLA-4 monoclonal antibody (IgG1κ) produced in Chinese hamster ovary cells by recombinant DNA technology. Excipients with known effect: Each ml of concentrate contains 0.1 mmol sodium, which is 2.30 mg sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). Clear to slightly opalescent, colourless to pale yellow liquid that may contain light (few) particulates and has a pH of 7.0 and an osmolarity of 260-300 mOsm/kg. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Melanoma YERVOY as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults, and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1). Renal cell carcinoma (RCC) YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • Immune Checkpoint Inhibitor Therapy-Associated Encephalitis: a Case Series and Review of the Literature
    Original article | Published 23 November 2020 | doi:10.4414/smw.2020.20377 Cite this as: Swiss Med Wkly. 2020;150:w20377 Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature Stuby Johanna, Herren Thomasb, Schwegler Naumburger Guidoc, Papet Claudiad, Rudiger Alaina a Internal Medicine, Department II, Limmattal Hospital Zurich, Schlieren, Switzerland b Cardiology, Department II, Limmattal Hospital Zurich, Schlieren, Switzerland c Neurology, Department II, Limmattal Hospital Zurich, Schlieren, Switzerland d Oncology/Haematology, Department II, Limmattal Hospital Zurich, Schlieren, Switzerland Summary EEG should be performed. Therapy with intravenous corti- costeroids is recommended. Steroid unresponsiveness is BACKGROUND: Immune checkpoint inhibitors (ICIs) can rare and should lead to a review of the diagnosis. Alterna- cause a wide spectrum of immune-related adverse events, tive treatment options are IVIG, plasma exchange therapy including encephalitis. To date, no prospective ran- and rituximab. domised controlled trials examining the patient charac- teristics, treatment and outcomes of ICI-associated en- Keywords: immune checkpoint inhibitor, nivolumab, pem- cephalitis have been published. Therefore, we aimed to brolizumab, ipilimumab, encephalitis review case reports and to provide recommendations for the management of ICI-associated encephalitis. Introduction METHODS: A literature search using Google Scholar and Immune checkpoint inhibitors (ICIs) re-establish the anti- PubMed was performed in December 2019. Published tumour activity of T-lymphocytes by blocking immune in- case reports and case series of ICI-associated encephali- hibitory receptors such as programmed cell death protein 1 tis were reviewed, and a case series from the Limmattal (PD-1, e.g., nivolumab, pembrolizumab and lambrolizum- Hospital in Schlieren, Switzerland was added.
    [Show full text]
  • The Antitumor Immunity of Ipilimumab: (T-Cell) Memories to Last a Lifetime?
    Published OnlineFirst February 15, 2012; DOI: 10.1158/1078-0432.CCR-12-0409 Clinical Cancer CCR Translations Research Commentary on Prieto et al., p. 2039 The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime? Michael A. Postow1,3, Margaret K. Callahan1,3, and Jedd D. Wolchok1,2,3,4 Ipilimumab has shown an overall survival benefit in 2 randomized phase III studies. A minority of patients achieve long-term disease control, highlighting the potential of this immunotherapeutic approach. In ongoing efforts, investigators are continuing to characterize these patients’ unique clinical courses and correlate their responses with underlying mechanisms of antitumor immunity. Clin Cancer Res; 18(7); 1821–3. Ó2012 AACR. In this issue of Clinical Cancer Research, Prieto and col- Prieto and colleagues have assembled findings from the leagues (1) report long-term follow-up data for 177 patients largest reported long-term clinical experience with ipilimu- treated with ipilimumab in some of the earliest trials in its mab. They provide updated data from 3 previously development. Their results underscore the remarkable, published studies that examined ipilimumab with gp100 durable benefits a subset of patients with melanoma achieve vaccination [protocol 1 (6)]; ipilimumab with concomitant from ipilimumab, hint at the promise of combining ipili- IL-2 [protocol 2 (7)]; and ipilimumab via a strategy of mumab with interleukin 2 (IL-2), and raise the provocative intrapatient dose escalation (Æ gp100) until occurrence of question of whether, in some patients, metastatic melano- response or intolerable side effects [protocol 3 (8)]. The ma can be cured. authors evaluate a total of 177 patients treated with ipili- Ipilimumab (Yervoy; Bristol-Myers Squibb) is a fully mumab, with a median follow-up of 92, 84, and 71 months, human monoclonal antibody that blocks cytotoxic respectively.
    [Show full text]
  • Ipilimumab for the Treatment of Metastatic Melanoma Hansoo Kim*, Samantha Comey, Karl Hausler and Greg Cook
    Kim et al. Journal of Pharmaceutical Policy and Practice (2018) 11:4 DOI 10.1186/s40545-018-0131-4 RESEARCH Open Access A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma Hansoo Kim*, Samantha Comey, Karl Hausler and Greg Cook Abstract Background: Australian Government subsidisation of ipilimumab for the treatment of patients with metastatic melanoma was conditional on the sponsor entering a ‘managed entry scheme’ to assess the 2-year overall survival rate in metastatic melanoma patients who received ipilimumab in the first year of Pharmaceutical Benefits Scheme listing. Methods: All unresectable stage IIIc / IV metastatic melanoma patients treated with at least one dose of ipilimumab therapy in Australia from the PBS listing date to a time point 12 months later (i.e. from 1-Aug-2013 to 31-Jul-2014) were invited to participate. Overall survival at 2 years post treatment initiation was measured, with Cox regression analysis used to examine the relationship between survival and patient baseline characteristics. Results: The evaluable population (910 patients) was on average 63.3 years old, male (70.1%) and treated in a public hospital (64.4%) in an urban area (76.5%). The majority of patients were treatment naïve (63.3%), did not have brain metastases (71.1%), and were classified as ECOG performance status 0 or 1 (90.4%). The 2 year overall survival rate was conservatively calculated to be at least 23.9% and potentially as high as 34.2%. A significant difference in overall survival at 2 years was demonstrated across the categories of ECOG performance status (p < 0.0001), M-status (p = 0.0005) and treatment status (p = 0.0114).
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Yervoy® (Ipilimumab)
    Yervoy® (ipilimumab) (Intravenous) -E- Document Number: MODA-0548 Last Review Date: 07/01/2021 Date of Origin: 07/01/2020 Dates Reviewed: 07/2020, 10/2020, 12/2020, 04/2021, 07/2021 I. Length of Authorization Coverage will be provided for six months and may be renewed (unless otherwise specified). Renal Cell Carcinoma (RCC)/Cutaneous Melanoma (excluding adjuvant therapy)/Colorectal Cancer (CRC)/Hepatocellular Carcinoma (HCC)/Uveal Melanoma/CNS metastases from Melanoma (combination therapy with nivolumab) 1,6,9,10,11,17-19,20,27,29,33,39-41 • Coverage will be provided for 12 weeks (may be extended to 16 weeks if 4 doses were not administered within the 12 week time frame) and may not be renewed*. * Requests for Cutaneous Melanoma may be renewed if the patient meets the provisions for re- induction therapy. Non-Small Cell Lung Cancer (NSCLC)/ Malignant Pleural Mesothelioma 1,12,24 • Coverage will be provided for up to a maximum of 2 years of therapy. Cutaneous Melanoma (adjuvant therapy) 1,6,17 • Coverage for adjuvant treatment will be provided for six months and may be renewed for up to a maximum of 3 years of therapy. CNS metastases from Melanoma (single agent therapy) 8,28 • Coverage will be provided for 12 weeks initially (may be extended to 16 weeks if 4 doses were not administered within the 12 week time frame). Coverage may be renewed in 6 month intervals thereafter. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: • Yervoy 200 mg/40 mL injection: o 5 vials per 84 days (initially up to 5 vials per 21 days x 4 doses) • Yervoy 50 mg/10 mL injection: o 3 vials per 84 days (initially up to 3 vials per 21 days x 4 doses) B.
    [Show full text]
  • Natalizumab May Control Immune Checkpoint Inhibitor–Induced Limbic Encephalitis
    CLINICAL/SCIENTIFIC NOTES OPEN ACCESS Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis Andreas F. Hottinger, MD, PhD, Rita de Micheli, MD,* Vanessa Guido, MD,* Alexandra Karampera, MD,* Correspondence Patric Hagmann, MD, PhD,* and Renaud Du Pasquier, MD Dr. Hottinger [email protected] Neurol Neuroimmunol Neuroinflamm March 2018;5:e439. doi:10.1212/NXI.0000000000000439 In recent years, new therapeutic approaches that restore the ability of the immune system to attack cancer cells have dramatically improved the outcome of various malignant tumors, including melanoma and lung cancer. Ipilimumab, a monoclonal antibody that binds and inhibits cytotoxic T-lymphocyte–associated antigen 4, and nivolumab, a monoclonal antibody that blocks programmed cell-death protein 1, have been approved. As these treatments, respectively, block T-cell inhibition and potentiate the activation of T cells, they may trigger – a number of neurologic immune-related adverse events,1 9 as illustrated here. We describe a 71-year-old woman who was diagnosed in 2014 with stage IV small-cell lung cancer and treated with 6 cycles of cisplatin/etoposide, followed by mediastinal and pro- phylactic cranial irradiation. Because of tumor progression in the lung and liver, she received a first dose of nivolumab 1 mg/kg, followed by ipilimumab 3 mg/kg. On day 4 following administration, she developed short-term memory deficits that worsened over the next 5 days. On admission, she was found to be disoriented in time and space and unable to recall any word after 5 minutes. Autobiographic memory was preserved. She presented dysexecutive disorder and was unable to read or write.
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • The Current State of the Art for Biological Therapies and New Small Molecules in Inflammatory Bowel Disease
    www.nature.com/mi REVIEW ARTICLE The current state of the art for biological therapies and new small molecules in inflammatory bowel disease Sudarshan Paramsothy1, Adam K. Rosenstein1,2, Saurabh Mehandru1,2 and Jean-Frederic Colombel1 The emergence of biologic therapies is arguably the greatest therapeutic advance in the care of inflammatory bowel disease (IBD) to date, allowing directed treatments targeted at highly specific molecules shown to play critical roles in disease pathogenesis, with advantages in potency and selectivity. Furthermore, a large number of new biologic and small-molecule therapies in IBD targeting a variety of pathways are at various stages of development that should soon lead to a dramatic expansion in our therapeutic armamentarium. Additionally, since the initial introduction of biologics, there have been substantial advances in our understanding as to how biologics work, the practical realities of their administration, and how to enhance their efficacy and safety in the clinical setting. In this review, we will summarize the current state of the art for biological therapies in IBD, both in terms of agents available and their optimal use, as well as preview future advances in biologics and highly targeted small molecules in the IBD field. Mucosal Immunology (2018) 11:1558–1570; https://doi.org/10.1038/s41385-018-0050-3 INTRODUCTION concerns regarding the safety of these agents have decreased Inflammatory bowel disease (IBD) incorporates a spectrum of with accumulating data. Although there is a slightly increased risk chronic, often progressive and disabling, inflammatory disorders of serious infections, this is lower than initially predicted and less of the gastrointestinal tract including Crohn’s disease (CD) and than the risk associated with steroid use.12 Concerns regarding ulcerative colitis (UC).
    [Show full text]